## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses	s)														
1. Name and Address of Reporting Person* STIGALL L. JEREMY				2. Issuer Name and Ticker or Trading Symbol ClearPoint Neuro, Inc. [CLPT]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)Director10% Owner					
(Last) (First) (Middle) C/O CLEARPOINT NEURO, INC., 120 S. SIERRA AVE., SUITE 100			3. Date of Earliest Transaction (Month/Day/Year) 08/20/2022							X Officer (give title below) Other (specify below)  GM, Biologics & Drug Delivery						
(Street) SOLANA BEACH, CA 92075				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)  Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	DLACII	(State)	(Zip)		T	able I	- Non	-Der	ivative	Securities	Acqui	ired, Disp	osed of, or l	Beneficially	Owned	
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	Execution any	A. Deemed xecution Date, if	(Instr. 8)		4. Securities Acqui (A) or Disposed of (Instr. 3, 4 and 5)		uired of (D)	5. Amour Beneficia	ant of Securities ally Owned Following d Transaction(s)		6. Ownership Form:	7. Nature of Indirect Beneficial Ownership	
				(1/101111)	2 uj ( 2 uu)		ode	V	Amoun	(A) or (D)	Price	(mour o			or Indirect (Instr. 4)	
Common S	Stock		08/20/2022			]	F		203 (1	)     1   1	\$ 13.24	42,692	(2)		D	
			Table II -				quire	cont the f d, Di	ained i form di	n this for splays a of, or Ben	rm are curre reficial	not requesting ntly valid	OMB con	formation spond unle trol numbe	ss	1474 (9-02)
(Instr. 3) P		(Month/Day/	n 3A. Deemed Execution Da any	4. Transaction Code Year) (Instr. 8)		5. Number		tions, convertible securi  6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Ta	itle and bunt of erlying urities tr. 3 and	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivati Security Direct ( or Indire	Beneficial Ownership (Instr. 4)	
				С	Code V	(A)	(D)	Date Exer	cisable	Expiration Date	n Title	Amount or Number of Shares				
Report	ing O	wners														

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
STIGALL L. JEREMY C/O CLEARPOINT NEURO, INC. 120 S. SIERRA AVE., SUITE 100 SOLANA BEACH, CA 92075			GM, Biologics & Drug Delivery				

## **Signatures**

/s/ Richard F. Mattern by Power of Attorney for Jeremy L. Stigall	08/22/2022
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted
- (2) Includes 1,369 shares of common stock acquired through purchases pursuant to the Employee Stock Purchase Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.